1 XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2

2 accelerates the recovery of mild to moderate COVID-19 patients and keeps

3

its neutralizing activity against Omicron and its subvariants.

4

Garyfallia Poulakou¹, Pierre-Joseph Royer², Nikolai Evgeniev³, Gwénaëlle Evanno²,
Françoise Shneiker², Bernard Vanhove², Odile Duvaux², Stéphane Marot⁴ Vincent Calvez⁴.

7

¹3rd Department of Internal Medicine, Medical School, Sotiria General Hospital, National and

9 Kapodistrian University of Athens, 11527 Athens, Greece.

10 ²Xenothera, Nantes, France.

³Complex Oncology Center, Department of Medical oncology, Russe, Bulgaria.

⁴Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé

13 Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière

- 14 Hospital, Department of Virology, Paris, France.
- 15

16

17 <u>ABSTRACT</u>

Background: XAV-19 is a glyco-humanized swine polyclonal antibody targeting SARS-CoV-2. The safety and clinical efficacy of XAV-19 was investigated in patients with a WHO score of 2 to 4 in the WHO 7-point ordinal scale. The activity of XAV-19 against Omicron and its subvariants was assessed *in vitro*.

Methods: A phase II/III, multicentric randomized double-blind placebo-controlled, clinical trial was conducted to evaluate the safety and clinical efficacy of XAV-19 in inpatients with COVID-19 requiring or not oxygen therapy and outpatients not requiring oxygen (EUROXAV trial, NCT04928430). Most patients were not vaccinated. The primary endpoint was the proportion of patients with an aggravation of COVID-19 within 8 days after treatment. Binding and neutralization of Omicron or its subvariants by XAV-19 was investigated by ELISA or with a whole virus neutralization assay.

Results: Patients received either 150mg of XAV-19 (N=139) or placebo (N=140). Low enrolment forced the premature trial termination. XAV-19 was well tolerated. No difference in the primary endpoint, nor in the proportion with an improvement at day 8 (secondary endpoint) was observed between the 2 groups. For patients not requiring oxygen therapy, XAV-19 reduced the time to improvement significantly (7 days *vs* 14 days p=0.0159). Neutralizing activity against Omicron and BA.2, BA2.12.1, BA.4/5 and BQ1.1 subvariants was shown in vitro.

Conclusions: XAV-19 did not reduce the aggravation in COVID-19 patients. While it did not bring any benefit to patients requiring oxygen, it reduced the time to improvement for patients not requiring oxygen (WHO score 2 or 3). These preliminary clinical data might indicate a therapeutic potential for patients with mild to moderate COVID-19 requiring supplementation with anti-SARS-CoV-2 neutralizing antibodies.

41 Key word: SARS-COV-2, (Glyco-Humanized) polyclonal antibody, XAV-19, Omicron.

42 **INTRODUCTION**

Since the beginning of the Coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), mass vaccination campaigns from December 2020, dramatically reduced the impact of SARS-CoV2, limiting the pandemic and reducing the number of deaths. Yet, prophylactic or therapeutic drugs are still needed for immunocompromised patients or people who do not respond to the vaccination (1,2).

Numerous neutralizing monoclonal antibodies (mAb) have been developed against 49 50 SARS-CoV-2. Most of them were raised against the original Wuhan-type virus and see their 51 neutralization potential abrogated or reduced against variants. Moreover, mAb may favor the 52 emergence of SARS-CoV-2 resistant variant in immunocompromised patients (3). Also, 53 approved anti-SARS-CoV-2 mAb are no more recommended since end 2022 since they are 54 unlikely to be effective against emerging strains of SARS-CoV-2 (4-6). Owing to their 55 potential to bind multiple target epitopes and maintain their neutralizing activity despite mutations, polyclonal antibodies (pAbs) from animal origin represent a promising approach 56 57 against COVID-19 (7,8). Hyperimmunization of qualified and selected animals guarantees 58 large volumes of high-titer and controlled pAb. Moreover, the whole process of production 59 and purification is quick, affordable and compatible with clinical manufacturing. Thereby, 60 pAbs against SARS-CoV-2 are being tested in clinical trials (9-11).

We developed XAV-19, a swine glyco-humanized polyclonal antibody (GH-pAb) directed against the Wuhan-type SARS-CoV-2 RBD (12). XAV-19 is produced in alpha 1,3galactosyltransferase (GGTA1)/cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) double KO pigs, preventing the formation of immune complexes thus avoiding post-infusion serum sickness and allergies (13). Clonal origin of the double KO pigs

| 66 | limits the risk for batch-to-batch variation. XAV-19 broadly neutralizes variants (14) and has |
|----|--|
| 67 | been introduced in clinic since 2020 where it displayed no major safety issues in a phase IIa |
| 68 | clinical trial for patients under oxygen (9). Considering the later publications on the benefits |
| 69 | of anti-SARS-CoV-2 antibodies when administered early, we investigated the clinical impact |
| 70 | of XAV-19 for patients (in- or out-) suffering from mild to moderate COVID19. The results |
| 71 | of the EUROXAV study (NCT04928430, EudraCT: 2020-005979-12), an international, |
| 72 | placebo-controlled, double-blind, randomized clinical trial designed to evaluate the efficacy |
| 73 | and safety of XAV-19 in patients with moderate COVID-19 requiring or not oxygen therapy |
| 74 | are presented. Besides, as SARS-CoV-2 keep evolving, the activity of XAV-19 against |
| 75 | Omicron and its current spreading subvariants was tested. |

77 **METHODS**

78 Phase II/III Trial

Study design. EUROXAV (NCT04928430; EudraCT: 2020-005979-12) was a multicenter, international phase II/III, double-blind, placebo-controlled, randomized clinical trial conducted in 14 hospitals from 5 countries (Bulgaria, Greece, Romania, Spain, Turkey) between March 2021 and October 2022. This trial followed the International Council for Harmonization E6 guideline for good clinical practice and the principles of the Declaration of Helsinki. An independent data safety monitoring board (DSMB) examined the data for safety on a regular basis during the trial.

86

87 Participants. Adult patients must have SARS-CoV-2-confirmed infection (RT-PCR, RT-88 qPCR or antigen test in the last 10 days) and present signs of respiratory disease with at least 89 2 clinical symptoms related to COVID-19 started less than 10 days prior to screening visit. 90 Patients should have SpO2 > 90% (at ambient air) and require or not low-flow oxygen 91 therapy (score 2, 3 or 4 on WHO clinical progression 7-point ordinal scale (15)). Exclusion 92 criteria were a positive SARS-CoV-2 test > 10 days, multiorgan failure, immediate ICU 93 hospitalization, critical respiratory illness, requirement of oxygenation at flow rate > 6L/min, 94 or signs of severe systemic illness (respiratory rate ≥ 30 per min, heart rate ≥ 125 per min, 95 PaO2/FiO2 < 300), participation of another trial, pregnancy or breastfeeding. Eligible patients 96 were randomized in a 1:1 ratio to receive either XAV-19 (150mg) diluted in sterile NaCl 97 0.9% or placebo (NaCl 0.9% only) as a 1-hour intravenous perfusion. Randomization was 98 stratified by center and by WHO score (WHO score = 2 or 3 versus WHO score = 4). Patients 99 were monitored during the infusion and the following hour. On the investigator judgement, 100 the patient was either hospitalized or discharged (ambulatory patients). Dexamethasone, 101 antithrombotic prophylaxis, antibiotics and antiviral medication (except anti-SARS-CoV-2

mAb or convalescent plasma) were allowed according to the judgement of the investigatorand to the national guidelines or standard of care.

104

Sample size calculation. Sample size calculation initially assumed 15% progression of COVID-19 in the placebo arm versus 8% in the XAV-19 arm and a two-sided 5% type I error rate. A sample of 650 patients would provide the trial with 80% power. Considering a dropout rate of 25%, 870 patients were planned.

109

Primary endpoint. The primary endpoint was the proportion of patients with an aggravation of COVID-19 within 8 days. The aggravation was defined as a worsening of the score of at least 1 point on the WHO 7-point ordinal scale compared to the score at randomization.

113

114 Secondary endpoints. Secondary endpoints were proportion of patients with an aggravation 115 of COVID-19 within 8 days after treatment (defined as a worsening of the score of at least 2 116 points on the WHO clinical progression 7-point ordinal scale compared to the score at 117 randomization); proportion of patients with an aggravation/improvement of COVID-19 118 between day 8 and day 15 (defined as a worsening/improvement of the score of at least 1 119 point on the WHO 7-point ordinal scale); time to aggravation/improvement measured by the 120 proportion of patients with an aggravation/improvement at each measurement days (3, 5, 8, 121 15) after randomization. Safety outcomes included the cumulative incidence of any Adverse 122 Event (AE). A stratified log rank-test will be used to compare treatment effect between 123 groups, after adjustment on the stratification variables at baseline.

124

125 Statistical analyses. The global alpha type I error with bilateral hypotheses for this study was 126 fixed at 5%. Binary logistic regression model was performed for the primary efficacy

127 analysis. Association between the randomization group and the progression of COVID-19 128 was adjusted on centre, WHO score, country, age, body mass index (BMI), gender and 129 comorbidities (defined as BMI>30, diabetes DNID, diabetes DID, cardiac disorder, vascular disorder, hypercholesterolemia, renal failure, lung disease COPD and/or asthma). For efficacy 130 131 analyses, the strategy "Missing=Failure" is performed for patients who withdraw before D8 or 132 for patients with missing data. Under this strategy, patients without an available assessment at 133 D8 will be considered as having an aggravation. Replacement of missing data is done in the 134 ITT and TARGET populations. The comparisons between XAV-19 group and placebo group 135 of two or more qualitative variables was made using the χ^2 test, the continuity-corrected χ^2 136 test or Fisher exact test, according to the expected values under the assumption of 137 independence. Comparisons of quantitative variables between XAV-19 and placebo groups were made using a Student t-test (parametric test comparing means) or Mann-Whitney-138 139 Wilcoxon test (non-parametric test comparing ranks) depending on the distribution of the 140 variable of interest. A log rank test was used to compare time to aggravation/improvement 141 between randomization groups. Kaplan-Meier curves are presented by randomization groups 142 and by WHO score at baseline.

143

144 Spike/ACE-2 neutralization assay. Recombinant SARS-CoV-2 RBD (1µg/ml in 145 carbonate/bicarbonate buffer pH 9.0) were immobilized overnight at 4°C on Maxisorp 146 microtiter plates. After washes and saturation with PBS-Tween 0.05%-BSA2%, successive 147 dilutions of XAV-19 or tixagevimab/cilgavimab were added for 30 min, followed by ACE-2-148 mFc Tag ligand (Sino Biological; final concentration 125 ng/ml). After 1h incubation and 149 washing, the ACE-2 mFc Tag was revealed using a peroxidase-conjugated anti-mouse 150 secondary antibody. Binding intensity was revealed by addition of TMB. Reaction was 151 stopped with 50 µl of 1M H2S04 and optical density was taken at 450 nm.

152 Cytopathogenic Effect (CPE). Vero cells (CCL-81) and Vero E6 cells (CRL-1586) were 153 obtained from ATCC. SARS-CoV-2 clinical isolates were isolated from SARS-CoV-2 RT-154 PCR positive patients and viral stocks were generated by one passage on Vero cells. Titration of viral stock was performed on Vero E6 by limiting dilution assay allowing calculation of 155 156 tissue culture infective dose 50% (TCID50). Serial dilutions of XAV-19 (50µl) were 157 incubated with 50µl of virus (2 x 10E3 TCID50/ml) in a 96-well plate at 37°C for 60min in 8 158 replicates. Hundred µl of Vero E6 cell (3 x 10E5 cells/ml) were then added to the mixture and 159 incubated at 37°C, 5% CO2 until microscopy examination on day 4 to assess CPE. For viral 160 load (VL) quantification, RNA extraction of the 8 pooled replicates of each XAV-19 dilution 161 was performed with NucliSENS EasyMag (BioMerieux) according to manufacturer's 162 protocol. The relative VL were assessed from cycle threshold values for ORF1ab gene 163 obtained by the TaqPathTM COVID-19 RT-PCR (ThermoFisher, Waltham, USA) and by 164 linear regression in log10 copies/ml with a standard curve realized from a SARS-CoV-2 165 positive nasopharyngeal sample quantified by Droplet-Digital PCR (Bio-Rad).

166

167

169 **RESULTS**

170 Phase II/III

171 Demographic and patient characteristics. EUROXAV was initiated in 2021 and expected 172 to enrol 870 patients. Yet, due to the very low enrolment rate, the study was unlikely to be 173 completed in a reasonable timeline and was suspended on October 31, 2022. An interim blind 174 analysis was performed in November 2022, and the results were shared with the Independent 175 DSMB who recommended to stop the study. At that time, 293 patients with confirmed 176 COVID-19 were screened. Eligible patients were randomized to receive XAV-19 (N=139) or 177 placebo (N=140) (Figure 1). Final analyses were performed on target population defined as 178 ITT patients having received at least one dose of treatment and fulfilling the main inclusion 179 criteria, *i.e.* aged 18 or over, weighing between 40 and 120kg at the time of signing the 180 informed consent, requiring or not low-flow oxygen therapy (≤6L/min) with WHO score at 2, 181 3 or 4, (129 and 130 patients in the XAV-19 and the placebo arms respectively). The 182 demographic and clinical characteristic at baseline were similar between groups. The median 183 age was 56.4 years and 54.5% were male patients. Percentage of patients with a WHO score 184 of 2, 3 and 4 was 25.6, 45.7 and 28.7 in the XAV-19 arm and 25.4, 46.2, 28.5 in the placebo 185 arm (Table 1). While comorbidities were slightly higher in the XAV-19 arm (62% in XAV-19 186 group vs 49 in placebo group), both groups were comparable for age, gender, BMI, and WHO 187 score.

188

Primary efficacy endpoint. The primary endpoint was the proportion of patients with an aggravation of COVID-19 within 8 days after treatment. No differences on aggravation according to the treatment group was observed (12 *vs* 9 patients in the XAV19 and the placebo arm respectively, OR: 1.379, 95% CI 0.560 to 3.394, p=0.4831) (Table 2). Bivariate

analyses showed that age at screening or comorbidities were associated with COVID-19 progression, while gender, BMI, or WHO score were not (Table 2). Logistic regression confirmed the association between age (over 70) and aggravation of COVID-19 (p=0.001, OR = 6.675 [2.158; 20.645]) (not shown).

197

198 Secondary endpoints. There was no difference in the proportion of patients with COVID-19 199 aggravation within 8 days of treatment in the XAV-19 arm vs the placebo arm. Proportion of 200 patients with COVID aggravation at day 15 was similar between groups. Proportion of 201 patients with COVID-19 aggravation/improvement at day 15 vs day 8 was also similar 202 between XAV-19 and placebo arms (not shown). Although proportions of 203 aggravation/improvement were not different between groups, improvement did occur earlier 204 in the XAV-19 arm (p=0.0340) (Figure 2A). This benefit was even more significant for non-205 hospitalized patients (WHO score of 2 at day 1) or patients not requiring supplemental oxygen 206 (WHO score of 2 or 3 at day 1) (p=0.0003 and p=0.0159) while not significant for 207 hospitalized patients (WHO score of 3 or 4) or hospitalized patients requiring supplemental 208 oxygen (WHO score of 4) (p=0.7511 and p=0.8059). Furthermore, median time to 209 improvement was reduced in the XAV-19 arm compared to the placebo one (4 days vs 14 210 days and 7 days vs 14 days for patients with a WHO score at baseline of 2 and 2/3 211 respectively) (Figure 2B). By contrast, time to aggravation was not different between XAV-212 19 and placebo groups (not shown).

213

Safety. A total of 83 adverse event (AE) (45 in the XAV-19 arm and 38 in the placebo arm)
were observed from 29 patients in each group (Table 3). The percentage of mild/moderate AE
in the XAV-19 arm was 91% (*vs* 76.3% in the placebo arm). Twenty-two severe AE (SAE)
were reported in the XAV-19 group compared to 13 in the placebo group. None of them were

considered as related by the investigators. Interestingly, SAE > 3 account for 86% of SAE in the XAV-19 arm *vs* 92% in the placebo arms. Number of fatal SAE was equivalent between the two groups with 5 deaths in each group, from respiratory failure, multi-organ failure or disease progression. No anaphylaxis or hypersensitivity reactions and no infusion-related events were reported in any patients receiving XAV-19.

223

- To further explore XAV-19 clinical potential, the neutralizing activity of XAV-19 against
 Omicron and its subvariants was determined.
- 226

227 In vitro antiviral activity

XAV-19 antiviral efficacy against Omicron and its subvariants. Binding of XAV-19 to
Omicron, BA.2, BA2.12.1, BA.4/5 and BQ1.1 RBD appeared slightly lower than binding to
the original strain RBD. Yet, similar plateau was reached whatever the variant tested (Figure
3A, top). In comparison, binding of the association tixagevimab/cilgavimab (Evusheld®) to
Omicron or BA.4/5 RBD was dramatically reduced, and binding to BQ1.1 RBD was
completely abolished. Although binding of BA2 and BA2.12.1 subvariants was less affected,
a lower plateau was obtained (Figure 3A, bottom).

235 XAV-19 neutralization potential was then tested in an RBD/ACE-2 binding 236 competition assay. Comparable dose response profiles with full neutralization by XAV-19 237 were obtained with all the variants tested (Figure 3B, left); IC50 was moderately increased 238 $(5.9 \pm 0.2 \text{ and } 9.1 \pm 0.6 \mu \text{g/mL}$ for Wuhan and Omicron RBD respectively). By contrast, 239 neutralization efficacy of tixagevimab/cilgavimab was limited to 60% for Omicron versus 240 100% for Wuhan RBD (Figure 3B, right). XAV-19 neutralization of viral infectivity was 241 confirmed by CPE assay using SARS-CoV-2 clinical isolates. XAV-19 neutralized 100% of 242 CPE for all the variants tested and reached 100% viral load reduction (Figure 3C) with

slightly varying NT50 concentrations. Interestingly, NT50 against Omicron was in the low
range in CPE and lower than for all other variants in VL assessment.

XAV-19 targets epitopes outside the Omicron mutations. Four main target epitopes
of XAV-19 (347-fasvyawnr-417, 409-qiapgqtgn-417, 445-vsgnynylyrlfrksnlkpferdisteiy-473
and 530-stnlvk-535) were identified on Omicron RBD by proteolytic epitope mapping (Figure
4, bold), including 6 amino acids out of the 17 (in blue) directly involved in ACE-2 receptor
binding. Among the 15 Omicron mutations in RBD (in yellow), only 2 lie inside the major
XAV-19 target epitopes (N417 and S446) compared to 5 for the association
tixagevimab/cilgavimab (underlined; K440, S446, N477, K478, A484)(16).

252

253

.

254 **DISCUSSION**

Although vaccination is now the primary option against SARS-CoV-2, therapeutic drugs are still needed for immunocompromised or at-risk individuals. The potential of anti-SARS-COV-2 mAb is today largely dampened by the continual emergence of resistant variants (4,5,17) and as SARS-CoV-2 will probably continue to mutate, robust and variant resistant treatments are still necessary.

260 The therapeutic potential of XAV-19 was investigated in the phase II/III EUROXAV 261 study. Treatment with XAV-19 was safe and well tolerated. The fact that no patient who 262 received XAV-19 had anaphylaxis or hypersensitivity reactions, confirms the validity of our 263 glyco-humanization strategy. Yet, our trial suffered from a low inclusion rate and was stopped 264 after inclusion of 293 patients. In addition, the proportion of worsening cases within the 265 placebo arm was far lower than initially expected (8% observed vs 15% expected). This 266 reduction in disease severity, although most patients were not vaccinated, might be due to the 267 improvement in the management of COVID-19 patient (18,19) and/or to the infection of 268 patients with the Omicron strain, known to be less pathogenic than the original one (20). 269 Therefore, the low frequency of events, and the reduced recruitment rate, lowered 270 dramatically the power of the study and the primary endpoint was not met. Nevertheless, we 271 showed that XAV-19 efficiently modulated the kinetic of COVID-19 disease as it accelerated 272 the clinical improvement of patients not requiring high-flow oxygen therapy (WHO score \leq 273 4). More precisely, XAV-19 benefits to patients not requiring oxygen, while it does not bring 274 any benefit to oxygen-dependent patients (WHO score 4). In that respect, our data match 275 recent studies showing the suitability of therapeutics antibodies in patients with mild to 276 moderate COVID-19 (21-23).

277

We have previously shown the neutralization efficiency of XAV-19, against the original Wuhan and the Alpha, Beta, Gamma and Delta variants (8). Here the neutralization

activity of XAV-19 against Omicron and its subvariants was confirmed, while the association
tixagevimab/cilgavimab (Evusheld®) lost its activity, as already published (17). Interestingly,
XAV-19 even neutralized BQ1.1 subvariant, against which most mAb or cocktails of mAb are
devoid of activity (17,24). Neutralization potency of XAV-19 was also confirmed on live
Omicron by CPE assay. As the correlation between neutralization ELISA and CPE assay had
been previously shown, (8), our data strongly suggest the ability of XAV-19 to neutralize live
Omicron subvariants.

287 Due to its high number of mutations (30 mutations in the spike protein, 15 in the 288 RBD), Omicron showed resistance to more than 80% of the therapeutic antibody candidate (25). Yet these mutations represent only 3% of the main target epitopes of XAV-19. The 289 290 transmissibility of SARS-CoV-2 results from a fine balance between affinity to ACE-2 and 291 capacity to escape immune response. The need to maintain sufficient affinity to ACE-2 292 probably limits SARS-CoV-2 RBD mutability as shown by the R493Q reversion mutation 293 observed on the Omicron variants (26). Whereas antibody avidity allows to overcome SARS-CoV-2 variability (25), our data confirm that targeting multiple alternative epitopes, grants 294 295 pAb to keep their binding and neutralization capacity (8). Thereby, the neutralizing activity of 296 XAV-19, was confirmed so far on the 5 main SARS-CoV-2 variants that have emerged since 297 the beginning of the pandemic.

Limitations of the study are the following. The 7-point ordinal scale WHO score as main endpoint, may suffer from discrepancies among practices in the different countries / hospitals; and standardized criteria for use of oxygen or hospitalization have not been implemented in this trial. Another limitation is the absence of information about vaccination

| 302 | though most | patients we | ere not | vaccinated | due to | the r | main | enrolment | period | from | Jan t | o Se | pt |
|-----|-------------|-------------|---------|------------|--------|-------|------|-----------|--------|------|-------|------|----|
|-----|-------------|-------------|---------|------------|--------|-------|------|-----------|--------|------|-------|------|----|

303 2021 (268 patients included) in locations where the vaccines were not available yet.

304

| 305 | Altogether our data support XAV19 as a potent and affordable therapeutic option in |
|-----|---|
| 306 | patients with mild to moderate COVID-19, that could complement mAb antibody strategies. |
| 307 | Today, absence of robust, variant resistant anti-SARS-COV-2 mAb therapy for |
| 308 | immunocompromised individuals remains a public health concern (27). XAV-19 could be |
| 309 | specially proposed for those high-risk patients. |

- **Funding:** This project has received funding from Bpifrance and from the European Union's
- 312 Horizon 2020 research and innovation programme under grant

| agreement |
|-----------|
|-----------|

| 313 | No 962036. | bp <mark>ifrance</mark> | SERVER CANTER |
|-----|------------|-------------------------|---------------|
| 314 | | | |

315

Acknowledgments: We wish to thank all the patients, family members and staff from all theunits that participated in the study.

318

- 319 EUROXAV study group: Todor Atanasov, Dan Corneci, Valentin Cuervas-Mons, Gheorghe
- 320 Lulian Diaconescu, Nikolay Evgeniev, Gerd Fätkenheuer, Elizabeth George, Rosen Georgiev,
- 321 Benoit Guery, Guillen Santiago Moreno, Bedreag Ovidiu-Horea, Diamantis Kofteridis, Ali
- 322 Mert, Symeon Metallidis, Hristo Metev, Cristina Mussini, Garyfallia Poulakou, Emmanuel
- 323 Roilides, Fehmi Tabak, Pilar Vizcarra.

324

Potential conflicts of interest. PJR, GE, FS, BV and OD are employees of Xenothera.

326

328 **References**

| 329 330 331 332 | 1. | DeWolf S, Laracy JC, Perales M-A, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. <i>Immunity</i> (2022) 55:1779–1798. doi: 10.1016/j.immuni.2022.09.006 |
|--|----|---|
| 333 334 335 336 337 | 2. | Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD, Ho A, Aston S, Wootton DG, Richter A, et al. Outcome of COVID- 19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. <i>PLoS Med</i> (2023) 20:e1004086. doi: 10.1371/journal.pmed.1004086 |
| 338 339 340 341 342 343 | 3. | Gupta A, Konnova A, Smet M, Berkell M, Savoldi A, Morra M, Van averbeke V, De Winter FHR, Peserico D, Danese E, et al. Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. <i>Journal of Clinical Investigation</i> (2023) 133:1–13. doi: 10.1172/JCI166032 |
| 344 345 346 347 | 4. | Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. <i>Lancet Infect Dis</i> (2022) 22:e311–e326. doi: 10.1016/S1473- 3099(22)00311-5 |
| 348 349 350 351 | 5. | Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of immune escape variants from antibody-based therapeutics against covid-19: A systematic review. <i>Int J Mol Sci</i> (2022) 23: doi: 10.3390/ijms23010029 |
| 352 353 354 | 6. | Widyasari K, Kim J. A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID- 19). <i>Antibodies</i> (2023) 12:5. doi: 10.3390/antib12010005 |
| 355 356 357 358 359 | 7. | Cunha LER, Stolet AA, Strauch MA, Pereira VAR, Dumard CH, Gomes AMO, Monteiro FL, Higa LM, Souza PNC, Fonseca JG, et al. Polyclonal F(ab')2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency. <i>iScience</i> (2021) 24: doi: 10.1016/j.isci.2021.103315 |
| 360 361 362 363 364 365 | 8. | Vanhove B, Marot S, So RT, Gaborit B, Evanno G, Malet I, Lafrogne G, Mevel E, Ciron C, Royer P-J, et al. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. <i>Front Immunol</i> (2021) 12:1–11. doi: 10.3389/fimmu.2021.761250 |
| 366 367 368 369 | 9. | Gaborit B, Dailly E, Vanhove B, Josien R, Lacombe K, Dubee V, Ferre V, Brouard S, Ader F, Vibet M, et al. Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS- CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a |

| 370 371 372 | | Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study. Antimicrob Agents Chemother (2021) 65:1–13. doi: 10.1128/AAC.01237-21 |
|---|-----|---|
| 373 374 375 376 377 378 379 | 10. | Lopardo G, Belloso WH, Nannini E, Colonna M, Sanguineti S, Zylberman V, Muñoz L, Dobarro M, Lebersztein G, Farina J, et al. RBD-specific polyclonal F(ab')2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. <i>EClinicalMedicine</i> (2021) 34:100843. doi: 10.1016/j.eclinm.2021.100843 |
| 380 381 382 383 384 | 11. | Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger AL, Bausch C, Luke T, Hoover K, et al. Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19. <i>J Infect Dis</i> (2023)1–6. doi: 10.1093/infdis/jiad013 |
| 385 386 387 388 389 | 12. | Vanhove B, Duvaux O, Rousse J, Royer PJ, Evanno G, Ciron C, Lheriteau E, Vacher L, Gervois N, Oger R, et al. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2. <i>Eur J Immunol</i> (2021) 51:1412–1422. doi: 10.1002/eji.202049072 |
| 390 391 392 393 | 13. | Dhar C, Sasmal A, Varki A. From "Serum Sickness" to "Xenosialitis": Past, Present, and Future Significance of the Non- human Sialic Acid Neu5Gc. <i>Front Immunol</i> (2019) 10:807. doi: 10.3389/fimmu.2019.00807 |
| 394 395 396 397 398 399 | 14. | Vanhove B, Marot S, So RT, Gaborit B, Evanno G, Malet I, Lafrogne G, Mevel E, Ciron C, Royer P-J, et al. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. <i>Front Immunol</i> (2021) 12:1–11. doi: 10.3389/fimmu.2021.761250 |
| 400 401 402 403 | 15. | Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. <i>New England Journal of Medicine</i> (2020) 382:1787–1799. doi: 10.1056/nejmoa2001282 |
| 404 405 406 407 408 | 16. | Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen RE, Case JB, Sutton RE, Gilchuk P, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nat Microbiol</i> (2021) 6:1233–1244. doi: 10.1038/s41564-021-00972-2 |
| 409 410 411 412 | 17. | Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck H-M, Pöhlmann S, Hoffmann M. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. <i>Lancet Infect Dis</i> (2023) 23:22–23. doi: 10.1016/S1473-3099(22)00733-2 |

| 413 414 415 416 417 | 18. | Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, Ke FY, Su SC, Liang KH, Yuan JPY, et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>J Biomed Sci</i> (2022) 29:1–36. doi: 10.1186/s12929-022-00852-9 |
|--|-----|--|
| 418 419 420 421 422 423 | 19. | Brady DK, Gurijala AR, Huang L, Hussain AA, Lingan AL, Pembridge OG, Ratangee BA, Sealy TT, Vallone KT, Clements TP. A guide to <scp>COVID</scp> -19 antiviral therapeutics: a summary and perspective of the antiviral weapons against <scp>SARS-CoV</scp> -2 infection. <i>FEBS J</i> (2022)1–31. doi: 10.1111/febs.16662 |
| 424 425 426 427 428 429 | 20. | Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL, Kall M, Bhatt S, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. <i>The Lancet</i> (2022) 399:1303–1312. doi: 10.1016/S0140-6736(22)00462-7 |
| 430 431 432 433 434 | 21. | Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, Sarkis E, Solis J, Zheng H, Scott N, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19. <i>JAMA</i> (2022) 327:1236. doi: 10.1001/jama.2022.2832 |
| 435 436 437 438 439 | 22. | Huang DT, McCreary EK, Bariola JR, Minnier TE, Wadas RJ, Shovel JA, Albin D, Marroquin OC, Kip KE, Collins K, et al. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge. <i>JAMA Netw Open</i> (2022) 5:e2220957. doi: 10.1001/jamanetworkopen.2022.20957 |
| 440 441 442 443 444 445 | 23. | O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas R V., Barouch DH, et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA (2022) 327:432–441. doi: 10.1001/jama.2021.24939 |
| 446 447 448 449 450 | 24. | Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, Grzelak L, Prot M, Mougari S, Planchais C, et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. <i>Nat Commun</i> (2023) 14:824. doi: 10.1038/s41467-023-36561-6 |
| 451 452 453 454 455 | 25. | Callaway HM, Hastie KM, Schendel SL, Li H, Yu X, Shek J, Buck T, Hui S, Bedinger D, Troup C, et al. Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. <i>Cell Rep</i> (2023) 42:112014. doi: 10.1016/j.celrep.2023.112014 |

| 456 457 458 459 460 | 26. | Huo J, Dijokaite-Guraliuc A, Liu C, Zhou D, Ginn HM, Das R, Supasa P, Selvaraj M, Nutalai R, Tuekprakhon A, et al. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. <i>Cell Rep</i> (2023) 42:111903. doi: 10.1016/j.celrep.2022.111903 |
|---------------------------------|-----|---|
| 461 462 463 464 | 27. | Casadevall A, Focosi D. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. <i>Journal of Clinical</i> <i>Investigation</i> (2023) 133:1–3. doi: 10.1172/JCI168603 |
| 465 | | |
| 466 | | |

467 **FIGURE LEGENDS**

468 Figure 1. Clinical Trial Design.

469

470 Table 1. Demographic and baseline characteristics by treatment groups.

471

Table 2. Bivariate analysis between categorical variables and aggravation of COVID-19.

473

Figure 2. Time to clinical improvement. Kaplan-Meier curves by randomization group on whole TARGET population (**A**) or on TARGET population with a score of 2, 2 to 3, 3 to 4 or 4 at baseline (**B**). Improvement was defined as a diminution of at least 1 point on the WHO score compared to the WHO score at day 1. Dotted lines represent the median time to improvement.

479

480 Table 3. Adverse and serious adverse events.

481

482 Figure 3: XAV-19 antiviral activity against Omicron and its subvariants. Binding of XAV-19 or Evusheld to Wuhan or Omicron and its subvariant RBD (A). XAV-19 or 483 484 Evusheld were added to RBD coated plates at the indicated concentration and revealed with an HRP-conjugated secondary anti-pig or anti-human antibody. Neutralizing activity of XAV-485 486 19 or Evusheld to Wuhan or Omicron and its subvariant RBD (B). Recombinant His-Tag-487 RBD pre-incubated with XAV-19 or Evusheld were added to human ACE2 coated plates. Bound RBD were then detected with HRP-conjugated anti-His-Tag antibody. Neutralizing 488 489 activity of XAV-19 on whole replicating viruses (C). Vero E6 cells were infected with Wuhan

| 490 | or Omicron | SARS-CoV-2 | strains. | CPE | was | assessed | by | microscopy | examination | and | viral | L |
|-----|------------|------------|----------|-----|-----|----------|----|------------|-------------|-----|-------|---|
|-----|------------|------------|----------|-----|-----|----------|----|------------|-------------|-----|-------|---|

- 491 load percentage was determined by quantitative RT-PCR.
- 492

| 493 | Figure 4: XAV-19 target epitopes lie outside the Omicron mutation sites. Amino acid |
|-----|--|
| 494 | sequence of the SARS-CoV-2 spike RBD variant Omicron and XAV-19 target epitopes |
| 495 | (amino acid sequence numbered according to DBSOURCE sequence reference |
| 496 | NC_045512.2). Bold: XAV-19 target epitopes confirmed by proteolytic epitope mapping; |
| 497 | blue: amino acids in contact with ACE-2; yellow: mutations found in Omicron, differentiating |
| 498 | from the original Wuhan RBD, underlined: Tixagevimab/Cilgavimab target epitopes. |
| 499 | |
| 500 | |
| 501 | |
| 502 | |
| 503 | |
| 504 | |
| 505 | |



Figure 1: Flow chart of the clinical trial

| Characteristic | XAV-19 | PLACEBO | Total |
|---|--------------|--------------|--------------|
| Characteristic | (N=129) | (N=130) | (N=259) |
| Age at screening, mean (SD) | 57.5 (15.0) | 55.2 (15.4) | 56.4 (15.2) |
| Nb of male patients, n (%) | 74 (57.4) | 67 (51.5) | 141 (54.4) |
| BMI, mean (SD) | 28.3 (4.7) | 28.2 (4.6) | 28.2 (4.7) |
| Current smoker, n (%) | 14 (11.0) | 16 (12.5) | 30 (11.8) |
| WHO score at day 1, n (%) | | | |
| WHO 2 | 33 (25.6) | 33 (25.4) | 66 (25.5) |
| WHO 3 | 59 (45.7) | 60 (46.2) | 119 (45.9) |
| WHO 4 | 37 (28.7) | 37 (28.5) | 74 (28.6) |
| Comorbidities [§] , n (%) | 80 (62.0) | 64 (49.2) | 144 (55.6) |
| Immunocompromised patients, n (%) | 11 (8.5) | 11 (8.5) | 22 (8.5) |
| Time between first COVID-19 symptoms and treatment in days, mean (SD) | 2.3 (2.3) | 2.6 (2.5) | 2.5 (2.4) |
| Vital signs | | | |
| Systolic blood pressure, mmHg, mean (SD) | 125.1 (14.6) | 124.8 (16.3) | 124.9 (15.5) |
| Diastolic blood pressure, mmHg, mean (SD) | 76.5 (9.4) | 75.9 (9.8) | 76.2 (9.6) |
| Body temperature, mean (SD) | 37.3 (0.7) | 37.2 (0.8) | 37.3 (0.7) |
| Respiratory examination | | | |
| Signs of pneumonia [¥] , n (%) | 122 (94.6) | 120 (93.0) | 242 (93.8) |
| Onset of the oldest COVID-19 symptom in days, mean (SD) | 5.5 (2.4) | 5.6 (2.6) | 5.5 (2.5) |
| SpO2 at ambient air (%), mean (SD) | 94.9 (1.8) | 94.7 (2.1) | 94.8 (1.9) |
| Patients under O2 supplementation, n (%) | 37 (28.7) | 37 (28.5) | 74 (28.6) |

¥: determined by chest X ray, CT scan or auscultation §: BMI>30, diabetes DNID, diabetes DID, cardiac disorder, vascular disorder, hypercholesterolemia, renal failure, lung disease COPD and/or asthma

Table 1: Demographics and baseline characteristics by treatment group.

| Parameters | No Worsening N=238 | Worsening N= 21 | Total N=259 | P-values | OR [95/% IC] |
|--------------------------------------|-----------------------|--------------------|----------------|----------|-----------------------|
| Treatment, n (%) | | | | | |
| XAV19 | 117 (90.7) | 12 (9.3) | 129 | | |
| PLACEBO | 121 (93.1) | 9 (6.9) | 130 | 0.4831 | 1.379 [0.560; 3.394] |
| Age at screening, n (%) | | | | | |
| ≤ 50 years | 87 (97.8) | 2 (2.2) | 89 | | |
| > 50 years | 151 (88.8) | 19 (11.2) | 170 | 0.0124 | 5.473 [1.245; 24.061] |
| ≤ 60 years | 144 (96) | 6 (4) | 150 | | |
| > 60 years | 94 (86.2) | 15 (13.8) | 109 | 0.0045 | 3.829 [1.435; 10.221] |
| \leq 70 years | 196 (95.6) | 9 (4.4) | 205 | | |
| > 70 years | 42 (77.8) | 12 (22.2) | 54 | 0.0001 | 6.222 [2.464; 15.712] |
| ≤ 80 years | 230 (92.7) | 18 (7.3) | 248 | | |
| > 80 years | 8 (72.7) | 3 (27.3) | 11 | 0.0498 | 4.792 [1.169; 19.645] |
| Gender, n (%) | | | | | |
| Male | 130 (92.2) | 11 (7.8) | 141 | | |
| Female | 108 (91.5) | 10 (8.5) | 118 | 0.8433 | 0.914 [0.374; 2.233] |
| BMI, mean (SD) | 28.2 (4.8) | 27.8 (2.6) | 28.2 | | |
| Weight range n (%) | | | | | |
| Malnutrition : < 18.5 | 0 | 0 | 0 | | |
| Normal weight: [18.5;25] | 65 (97) | 2 (3) | 67 | | |
| Overweight: [25;30] | 92 (88.5) | 12 (11.5) | 104 | | |
| Moderate obesity: [30;35] | 61 (92.4) | 5 (7.6) | 66 | | |
| Severe obesity: [35;40] | 15 (6.3) | 0 (0) | 15 | | |
| Morbid or massive obesity: ≥ 40 | 5 (2.1) | 1 (5.0) | 6 | 0.1561 | NA |
| WHO score at day 1, n (%) | | | | | |
| WHO 2/3 | 170 (91.9) | 15 (8.1) | 185 | | |
| WHO 4 | 68 (91.9) | 6 (8.1) | 74 | 1 | 1.000 [0.372; 2.685] |
| Comorbidities, n (%) | | | | | |
| NO | 111 (96.5) | 4 (3.5) | 115 | | |
| YES | 127 (88.2) | 17 (11.8) | 144 | 0.0147 | 3.715 [1.214; 11.368] |

Table 2: Bivariate analysis between categorical variables and aggravation of COVID-19.



Figure 2 : Time to clinical improvement

| | XAV-19 (N=139) | | Placebo (N=140) | |
|--|--------------------|-------------------------|--------------------|-------------------------|
| | Number of patients | Number (%) of AE/SAE | Number of patients | Number (%) of AE/SAE |
| Any adverse event, N (%) | 29 | 45 (54.2) | 29 | 38 (45.8) |
| Mild/moderate AE, N (%/number of AE) | | 41 (91.1) | | 29 (76.3) |
| Related to XAV-19 or placebo, N (%/number of AE) | 8 | 9 (20.0) | 5 | 5 (13.2) |
| Any SAE, N (%) | 10 | 22 (62.9) | 9 | 13 (37.2) |
| SAE>3 N (%/number of SAE) | 9 | 19 (86.3) | 8 | 12 (92.3) |
| SAE related | 0 | 0 | 0 | 0 |
| Infusion-related events | 0 | 0 | 0 | 0 |
| Death | 5 | | 5 | |
| Cause of death | | | | |
| Respiratory failure | 3 | | 4 | |
| Disease progression | 0 | | 1 | |
| Multiorgan failure | 1 | | 0 | |
| Cytokine storm | 1 | | 0 | |

Table 3 : Adverse events and serious adverse events



Tixagevimab/Cilgavimab





Tixagevimab/Cilgavimab





Figure 3: XAV-19 antiviral activity against Omicron and its subvariants

319-rvqptesivrfpnitnlcpfdevfnatr**fasvyawnr**krisncva 364-dysvlynlapfftfkcygvsptklndlcftnvyadsfvirgdevr**qiapgqtgn**iadynyk 425-lpddftgcviawnsn<u>k</u>ldsk**vsgnynylyrlfrksnlkpferdisteiy** 474-qag<u>nk</u>pcngv<mark>a</mark>gfncyfplrsysfrptygvghqpyrvvvlsfellha 521-patvcgpkk**stnlvk**nkcvnf-541

- X : XAV-19 epitopes
- X : AA involved in ACE2 binding
- X : Omicron mutations
- <u>X</u> : Tixagevimab/Cilgavimab epitopes

Figure 4: XAV-19 target epitopes lying outside the Omicron mutation sites